title: Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women.
abstract: OBJECTIVE
  To investigate the effects of tibolone on carbohydrate metabolism, and to compare these effects with those of a sequential regimen of conjugated equine estrogens and medrogestone.
  
  
  METHODS
  This was an open-label, multicentre, comparative study. Seventy-two postmenopausal women were randomized to receive either tibolone 2.5 mg/day or conjugated equine estrogens 0.6 mg plus sequential medrogestone 5 mg (CEE/M) for six 28-day cycles. Carbohydrate metabolism was evaluated at baseline and after three and six cycles of treatment by an oral glucose tolerance test (OGTT). A blood sample was taken at 30, 60, 90 and 120 mm after glucose 75 mg dosing for determination of plasma glucose, insulin and connecting peptide (C-peptide) levels.
  
  
  RESULTS
  The changes from baseline of glucose, insulin and C-peptide area-under-the-curve (AUC) values were not statistically significant after 3 and 6 months of tibolone or CEE/M treatment. There was a small transitory decrease in HbA(1C) after three cycles of treatment with tibolone.
  
  
  CONCLUSIONS
  The effects of tibolone and CEE/M on carbohydrate metabolism were considered to have no clinical significance.
authors.affiliation: Department of Gynecology and Obstetrics, J.W. Goethe-University Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.
authors.forename: Inka
authors.initials: I
authors.lastname: Wiegratz
authors.forename: Franz
authors.initials: F
authors.lastname: Starflinger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Tetzloff
authors.forename: Beate
authors.initials: B
authors.lastname: Leifels-Fischer
authors.forename: Frans A
authors.initials: FA
authors.lastname: Helmond
authors.forename: Jeanne S E
authors.initials: JS
authors.lastname: Dericks-Tan
authors.forename: Herbert
authors.initials: H
authors.lastname: Kuhl
mesh_terms: D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D004334:Drug Administration Schedule; D020847:Estrogen Receptor Modulators / Q000494:pharmacology*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005951:Glucose Tolerance Test; D020249:Hormone Replacement Therapy; D006801:Humans; D007328:Insulin / Q000097:blood; D008524:Medrogestone / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D009426:Netherlands; D009652:Norpregnenes / Q000494:pharmacology*; D017698:Postmenopause
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D020847:Estrogen Receptor Modulators; D004966:Estrogens, Conjugated (USP); D007328:Insulin; D009652:Norpregnenes; D008524:Medrogestone; C027385:tibolone